过去十年,中国创新药产业的角色已经彻底改变。曾经被视为“追随者”的中国企业,如今正在重塑全球医药创新的版图——2025年我国在研药物数量占全球比例已经超过30%[1],仅次于美国。更值得关注的是,国产创新药license out交易量已占全球总数的38%[2],对外授权总金额更是突破了千亿美元,占到全球总交易额一半[3]。越来越多的海外药企,开始主动成为中国创新药公司的合作伙伴。2020-2025...
Source Link过去十年,中国创新药产业的角色已经彻底改变。曾经被视为“追随者”的中国企业,如今正在重塑全球医药创新的版图——2025年我国在研药物数量占全球比例已经超过30%[1],仅次于美国。更值得关注的是,国产创新药license out交易量已占全球总数的38%[2],对外授权总金额更是突破了千亿美元,占到全球总交易额一半[3]。越来越多的海外药企,开始主动成为中国创新药公司的合作伙伴。2020-2025...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.